Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|23|14|2113-2116

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.23, Iss.14, 2017-05, pp. : 2113-2116

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Strategies to Improve the Clinical Performance of Chimeric Antigen Receptor-Modified T Cells for Cancer

By  

Current Gene Therapy, Vol. 13, Iss. 1, 2013-02 ,pp. : 65-70

Bentham Science Publishers

Access to resources Recommend Favorite

Building Better Chimeric Antigen Receptors for Adoptive T Cell Therapy

By  

Current Gene Therapy, Vol. 10, Iss. 2, 2010-04 ,pp. : 77-90

Bentham Science Publishers

Access to resources Recommend Favorite

Life or Death of T Cells with Antigen-Specific Receptors - Using T Cells for Cancer Adoptive Immunotherapy / Gene Therapy

By  

Current Gene Therapy, Vol. 1, Iss. 3, 2001-09 ,pp. : 253-255

Bentham Science Publishers

Access to resources Recommend Favorite

EGFRvIII: an oncogene deletion mutant cell surface receptor target expressed by multiple tumour types

By Wikstrand C.J.   Sampson J.H.   Bigner D.D.  

Expert Opinion on Therapeutic Targets, Vol. 4, Iss. 4, 2000-08 ,pp. : 497-514

Informa Healthcare

Access to resources Recommend Favorite

Prospects and Limitations of T Cell Receptor Gene Therapy

By  

Current Gene Therapy, Vol. 5, Iss. 6, 2005-12 ,pp. : 583-593

Bentham Science Publishers

Access to resources Recommend Favorite